286
Views
0
CrossRef citations to date
0
Altmetric
Articles

SLAMF8 promotes the proliferation and migration of synovial fibroblasts by regulating the ERK/MMPs signalling pathway

, , , , , , & show all
Pages 294-300 | Received 08 Feb 2022, Accepted 23 Apr 2022, Published online: 04 May 2022

References

  • Guidelines ACoRSoRA. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheumat. 2002;46(2):328–346.
  • Taneja V. Sex hormones determine immune response. Front Immunol. 2018;9:1931.
  • Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130–136.
  • Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arth Res Ther. 2002;4(3):1–8.
  • Rupp I, Boshuizen H, Dinant H, et al. Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms. Scand J Rheumatol. 2006;35(3):175–181.
  • Han C, Robinson DW, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33(11):2167–2172.
  • Gullick NJ, Scott DL. Drug therapy of inflammatory arthritis. Clin Med. 2012;12(4):357–363.
  • Lee A, Qiao Y, Grigoriev G, et al. Tumor necrosis factor α induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2013;65(4):928–938.
  • Klein K, Kabala PA, Grabiec AM, et al. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. Ann Rheum Dis. 2016;75(2):422–429.
  • Neumann E, Lefèvre S, Zimmermann B, et al. Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med. 2010;16(10):458–468.
  • Guselnikov SV, Laktionov PP, Najakshin AM, et al. Expansion and diversification of the signaling capabilities of the CD2/SLAM family in xenopodinae amphibians. Immunogenetics. 2011;63(10):679–689.
  • Calpe S, Wang N, Romero X, et al. The SLAM and SAP gene families control innate and adaptive immune responses. Adv Immunol. 2008;97:177–250.
  • Shachar I, Barak A, Lewinsky H, et al. SLAMF receptors on normal and malignant B cells. Clin Immunol. 2019;204:23–30.
  • Zhang Q, Cheng L, Qin Y, et al. SLAMF8 expression predicts the efficacy of anti-PD1 immunotherapy in gastrointestinal cancers . Clin Transl Immunology. 2021;10(10):e1347.
  • Sugimoto A, Kataoka TR, Ito H, et al. SLAM family member 8 is expressed in and enhances the growth of anaplastic large cell lymphoma. Sci Rep. 2020;10(1):1–7.
  • Zou CY, Guan GF, Zhu C, et al. Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma. CNS Neurosci Ther. 2019;25(3):333–342.
  • Wu D, Zhang P, Ma J, et al. Serum biomarker panels for the diagnosis of gastric cancer. Cancer Med. 2019;8(4):1576–1583.
  • Sugimoto A, Kataoka TR, Ueshima C, et al. SLAM family member 8 is involved in oncogenic KIT-mediated signalling in human mastocytosis. Exp Dermatol. 2018;27(6):641–646.
  • Agere SA, Akhtar N, Watson JM, et al. RANTES/CCL5 induces collagen degradation by activating MMP-1 and MMP-13 expression in human rheumatoid arthritis synovial fibroblasts. Front Immunol. 2017;8:1341.
  • Guo Q, Wang Y, Xu D, et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6(1):1–14.
  • Nakken B, Papp G, Bosnes V, et al. Biomarkers for rheumatoid arthritis: from molecular processes to diagnostic applications-current concepts and future perspectives. Immunol Lett. 2017;189:13–18.
  • Wang J, Devenport J, Low JM, et al. Relationship between baseline and early changes in C‐reactive protein and interleukin‐6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res. 2016;68(6):882–885.
  • Ohata J, Zvaifler NJ, Nishio M, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol. 2005;174(2):864–870.
  • Ohori M. ERK inhibitors as a potential new therapy for rheumatoid arthritis. Drug News Perspect. 2008;21(5):245–250.
  • Tuncer T, Kaya A, Gulkesen A, et al. Matrix metalloproteinase-3 levels in relation to disease activity and radiological progression in rheumatoid arthritis. Adv Clin Exp Med. 2019;28(5):665–670.
  • Hattori Y, Kida D, Kaneko A. Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis. Clin Rheumatol. 2019;38(1):181–187.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.